List of Excipients in Branded Drug FLUTAMIDE

Generic Drugs Containing FLUTAMIDE

Company	Ingredient	NDC	Excipient
Cipla USA Inc	flutamide	69097-915	ALUMINUM OXIDE
Cipla USA Inc	flutamide	69097-915	D&C YELLOW NO. 10
Cipla USA Inc	flutamide	69097-915	FD&C BLUE NO. 1
Cipla USA Inc	flutamide	69097-915	FD&C BLUE NO. 2
Cipla USA Inc	flutamide	69097-915	FD&C RED NO. 40
Cipla USA Inc	flutamide	69097-915	FERRIC OXIDE RED
Cipla USA Inc	flutamide	69097-915	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in FLUTAMIDE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	FD&C BLUE NO. 2
1	FD&C RED NO. 40
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW

Flutamide Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Flutamide is an off-patent, oral nonsteroidal antiandrogen with limited commercial growth potential because of hepatotoxicity, declining use in prostate cancer, and competition from safer androgen-receptor pathway inhibitors. The strongest excipient opportunities are reformulation projects that improve dissolution, dose uniformity, swallowability, and supply-chain economics. Excipients cannot remove flutamide’s intrinsic liver-injury risk, so any commercial product must preserve strict hepatic monitoring and avoid formulations that materially increase systemic exposure without clinical justification.

What is the current commercial status of flutamide?

Flutamide was approved in the United States for use with an LHRH agonist in the treatment of metastatic prostate cancer. It is administered orally, historically as a 125 mg capsule three times daily, for a total daily dose of 375 mg [1].

Attribute	Flutamide
Active ingredient	Flutamide
Pharmacologic class	Nonsteroidal androgen-receptor antagonist
Common strength	125 mg
Conventional dosage forms	Immediate-release capsules and tablets
Primary historical use	Metastatic prostate cancer
Key safety limitation	Severe and sometimes fatal hepatic injury
Patent position	Original composition and early product protection expired
Regulatory position	Generic-drug market; limited branded commercial activity
Main competitors	Bicalutamide, nilutamide, abiraterone, enzalutamide, apalutamide, darolutamide
Commercial growth driver	Low-cost supply and differentiated formulation, not molecule exclusivity

Flutamide use has declined as physicians have adopted bicalutamide and newer androgen-deprivation therapies. The FDA label carries a boxed warning for hepatic injury and requires liver-function testing before treatment and at regular intervals during therapy [1].

The product is therefore better viewed as a low-cost generic platform than as a conventional branded-growth asset.

What patents protect flutamide, and when did exclusivity expire?

Flutamide’s composition-of-matter and early product exclusivity are no longer commercially meaningful in the United States. Generic manufacturers can compete through abbreviated new drug applications, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, and labeling.

Protection category	Current commercial relevance
Composition-of-matter patent	Expired
Original branded-product patents	Expired or no longer commercially blocking
Regulatory exclusivity	Expired
Formulation patents	No dominant, broadly recognized active estate identified for conventional immediate-release flutamide
Method-of-use patents	Limited practical value because the principal indication is longstanding and generic
Generic entry	Established

The Orange Book remains the primary FDA source for approved products, patent listings, exclusivity information, and therapeutic-equivalence designations [2]. Flutamide’s commercial position does not depend on a live composition patent or an active branded exclusivity period.

Are there Paragraph IV risks for flutamide?

Paragraph IV risk is low relative to newer products because the central flutamide patents expired decades ago. A new generic entrant would more likely face ordinary ANDA competition, manufacturing scrutiny, or bioequivalence questions than a patent injunction.

Potential litigation could still arise from:

• A newly developed modified-release formulation.
• A solid-dispersion or lipid-based formulation with a narrowly drafted composition claim.
• A pediatric or specialty dosage form.
• A manufacturing process that produces a distinct solid state or impurity profile.
• A method-of-use claim tied to a new clinical population.

Such claims would need a meaningful technical distinction from conventional flutamide capsules and tablets. A patent covering only routine excipient substitution would face substantial validity and obviousness pressure.

What excipients are used in flutamide capsules and tablets?

Conventional flutamide products use standard immediate-release excipients. Public product labels identify combinations such as lactose, starch or pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, and capsule-shell materials. Exact compositions vary by manufacturer and dosage form [3,4].

Formulation function	Common excipient options	Commercial purpose
Dilution	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Achieve capsule or tablet weight
Disintegration	Sodium starch glycolate, crospovidone, croscarmellose sodium	Support immediate release
Granulation or binding	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improve tablet strength and processability
Lubrication	Magnesium stearate, sodium stearyl fumarate	Reduce ejection and tooling problems
Flow improvement	Colloidal silicon dioxide	Improve powder handling
Capsule shell	Gelatin or hypromellose	Provide unit-dose delivery
Color and opacity	Titanium dioxide, approved colorants	Product identification and light protection
Solubilization	Surfactants or wetting agents	Improve dissolution where needed

The key development question is not whether a standard excipient can be used. It is whether the selected excipient produces a measurable benefit without creating a new stability, bioequivalence, safety, or manufacturing problem.

What is the best excipient strategy for flutamide?

The most commercially defensible strategy is a staged formulation program focused on dissolution and manufacturing reliability before pursuing high-complexity delivery technologies.

Immediate-release tablet or capsule optimization

A low-cost reformulation can use a conventional dry blend, wet granulation, or roller-compaction process. The target is consistent dissolution across commercial-scale batches, especially if the active pharmaceutical ingredient has variable particle size or poor flow.

Relevant development levers include:

• Particle-size control for flutamide API.
• Selection between microcrystalline cellulose and lactose-based fillers.
• Crospovidone or sodium starch glycolate for rapid disintegration.
• Low-level colloidal silicon dioxide for powder flow.
• Magnesium stearate optimization to avoid over-lubrication and delayed dissolution.
• Moisture control during granulation and storage.
• Light-protective packaging if supported by stability data.

This approach offers the highest probability of approval and the lowest capital requirement.

Amorphous solid dispersion

Flutamide is poorly water-soluble, making dissolution enhancement a plausible technical opportunity. An amorphous solid dispersion using polymers such as PVP, copovidone, or hypromellose acetate succinate could increase apparent solubility and reduce dissolution variability.

The commercial problem is exposure control. A formulation that substantially raises exposure could increase adverse-event risk, particularly in a drug with known hepatic toxicity. Development would therefore require:

• Comparative pharmacokinetic testing.
• Food-effect assessment.
• Solid-state characterization.
• Long-term physical stability.
• Evaluation of recrystallization.
• Dose proportionality testing.
• Liver-safety analysis.

A solid dispersion is most attractive where conventional products show inadequate dissolution or inconsistent bioavailability. It is less attractive as a purely incremental product with no demonstrated clinical or manufacturing benefit.

Lipid-based and self-emulsifying systems

Lipid-based formulations may improve dissolution and reduce dependence on gastrointestinal fluid volume. They could be relevant for a softgel or liquid-filled capsule.

The main risks are:

• Increased exposure.
• Food-effect variability.
• Capsule-shell compatibility.
• Oxidative degradation of lipid vehicles.
• More complex manufacturing and packaging.
• Higher cost than generic tablets.

For flutamide, a lipid system should not be positioned solely as a bioavailability enhancer. The development objective would need to be a defined benefit such as reduced interpatient variability or a lower dose with equivalent exposure.

Modified-release formulations

A sustained-release product could reduce dosing frequency from three daily administrations to once or twice daily. The commercial case is clear: lower pill burden and potentially better adherence.

The pharmacology is less favorable. Flutamide has an active metabolite, hydroxyflutamide, and any modified-release product would need to reproduce the clinically appropriate exposure profile for both parent drug and metabolite. Development would require:

• Parent and metabolite pharmacokinetic comparison.
• Nighttime and daytime exposure assessment.
• Dose-dumping studies.
• Fed and fasted testing.
• Alcohol-induced dose-dumping evaluation where relevant.
• Clinical assessment of hepatic safety.

A modified-release formulation could support a stronger patent position than a routine immediate-release product. It would also require substantially greater investment and regulatory work.

What formulation patents could protect a new flutamide product?

A new patent estate would need to focus on a specific technical formulation rather than the active ingredient itself.

Potential claim categories include:

1. A defined polymeric amorphous dispersion with specified drug loading and dissolution performance.
2. A lipid-based composition with a narrow excipient ratio and demonstrated exposure control.
3. A modified-release matrix using a defined hydrophilic or insoluble polymer system.
4. A low-moisture formulation with an impurity-control profile.
5. A multiparticulate dosage form with a specified release curve.
6. A pediatric granule or dispersible tablet with validated dose uniformity.
7. A capsule or tablet using a distinct solid-state form or particle-engineering method.
8. A manufacturing process that limits specified degradation impurities.

Patent strength would depend on measured performance. Claims based only on selecting one conventional filler over another would be weak. Claims supported by unexpected dissolution, stability, pharmacokinetic, or impurity results would be stronger.

Can excipients reduce flutamide hepatotoxicity?

No excipient should be assumed to eliminate or materially reduce flutamide’s intrinsic hepatotoxicity.

A formulation can change:

• Peak plasma concentration.
• Total exposure.
• Exposure variability.
• Parent-drug to metabolite ratios.
• Gastrointestinal tolerability.
• Adherence.

Those changes may affect clinical risk, but they do not establish hepatic safety. Any reformulation intended to reduce liver injury would require clinical evidence, not an excipient-based rationale.

The existing FDA labeling requires baseline and periodic liver-function testing. Patients with abnormal liver tests or clinical symptoms consistent with liver injury require prompt evaluation and potential discontinuation [1].

What FDA regulatory pathway applies to a new flutamide formulation?

A conventional generic tablet or capsule would normally proceed through an ANDA if it matches the reference product in active ingredient, dosage form, strength, route, and relevant performance characteristics.

A materially different product may require a 505(b)(2) application, particularly if it introduces:

• A new route.
• A new dosage form.
• A modified-release profile.
• A clinically meaningful formulation change.
• A new dosing regimen.
• A new indication or patient population.

The regulatory pathway affects the commercial thesis. An ANDA supports rapid, low-cost market entry but offers limited differentiation. A 505(b)(2) can support formulation-based differentiation and potentially new labeling, but requires greater clinical and regulatory investment [5].

What commercial opportunities exist for flutamide excipients?

Low-cost generic supply

The largest near-term opportunity is manufacturing efficiency. Suppliers can compete through:

• Direct compression with fewer process steps.
• Reduced tablet weight.
• Improved powder flow.
• Lower rejection rates.
• Better dissolution robustness.
• More efficient blister or bottle packaging.
• Excipient substitution that reduces supply-chain dependence.

This opportunity is price-sensitive and favors manufacturers with established generic infrastructure.

Once-daily modified release

A once-daily product could address adherence and differentiate from conventional three-times-daily dosing. The opportunity is technically credible but commercially constrained by competition from newer antiandrogens and the cost of proving equivalent exposure and safety.

Pediatric or low-dose delivery

Flutamide has been used outside its core approved prostate-cancer market, including in some androgen-related conditions. A dispersible tablet, granule, oral suspension, or dose-flexible multiparticulate product could improve administration for patients unable to swallow capsules.

This segment presents regulatory and liability challenges because off-label use does not automatically create an approved pediatric market. A company would need a defined target population, validated dosing, stability data, and an appropriate regulatory strategy.

Hospital and specialty formulations

A unit-dose, tamper-evident, moisture-controlled package could serve institutional settings. The commercial value would come from medication-management efficiency rather than therapeutic exclusivity.

Emerging-market supply

Flutamide may retain demand in markets where newer androgen-receptor inhibitors are less accessible. Geographic opportunity is strongest where:

• Generic pricing remains competitive.
• Prostate-cancer treatment protocols still include older antiandrogens.
• Local manufacturing supports lower cost.
• Regulatory requirements allow reliance on established reference products.

Local patent analysis remains jurisdiction-specific. U.S. expiration does not determine freedom to operate in India, China, Brazil, Mexico, Turkey, or other markets.

How does flutamide compare with competing antiandrogens?

Product	Dosing convenience	Safety position	Formulation opportunity	Commercial outlook
Flutamide	Poor, historically three times daily	Significant hepatic risk	Dissolution, modified release, pediatric delivery	Low-cost niche
Bicalutamide	Once daily	Generally more favorable hepatic profile	Limited incremental need	Stronger generic demand
Nilutamide	Once daily	Distinct pulmonary, visual, and hepatic concerns	Limited	Narrowing use
Enzalutamide	Once or twice daily	Seizure and drug-interaction considerations	High-value branded formulations	Stronger branded economics
Abiraterone	Daily with food requirements	Mineralocorticoid and hepatic monitoring	Food-effect and formulation work	Large commercial market
Darolutamide	Multiple daily dosing with food	Favorable interaction profile relative to some alternatives	High-value branded platform	Strong commercial position

Flutamide’s formulation opportunity is therefore defensive. It can improve usability and supply economics, but excipient innovation alone is unlikely to restore the market position held by newer therapies.

What patent litigation, licensing, and settlement activity affects flutamide?

No major current U.S. patent-litigation or settlement framework is central to conventional flutamide commercialization. The original branded market has been generic for many years, and the principal commercial barriers are clinical safety, market demand, and manufacturing economics.

Licensing could become relevant if a company develops:

• A proprietary dispersion platform.
• A controlled-release technology.
• A pediatric delivery system.
• A region-specific product with local registration rights.
• A combination product with a distinct regulatory strategy.

The most valuable deal structure would likely be a formulation-platform license rather than a molecule license. Flutamide itself has limited standalone licensing value because its core intellectual property has expired and its therapeutic use has contracted.

Key Takeaways

• Flutamide is an off-patent oral antiandrogen with established generic competition.
• The main commercial constraint is hepatotoxicity, not patent expiry.
• Conventional excipient optimization offers the lowest-risk opportunity.
• Amorphous dispersions and lipid systems may improve dissolution but could increase exposure.
• Modified release offers the clearest differentiation but requires substantial pharmacokinetic and safety work.
• Excipients cannot be marketed as eliminating flutamide’s liver risk without clinical evidence.
• A new patent estate would need specific composition, process, solid-state, or release claims supported by unexpected data.
• Commercial upside is greatest in low-cost generics, adherence-oriented delivery, specialty packaging, and selected emerging markets.
• A new formulation is more likely to require a 505(b)(2) strategy if it materially changes release, dosing, or clinical use.
• Flutamide is commercially weaker than bicalutamide and newer androgen-receptor pathway inhibitors.

FAQs About Flutamide Formulation and Excipient Opportunities

Can flutamide be reformulated as a once-daily tablet?

Yes, but a once-daily product would require evidence that parent-drug and active-metabolite exposure remains clinically appropriate. Modified-release development would likely require more than a routine ANDA strategy.

Which excipients are most suitable for improving flutamide dissolution?

Polymeric dispersion carriers, wetting agents, surfactants, and particle-engineering approaches are the leading options. The final choice must balance dissolution improvement against excessive systemic exposure and physical instability.

Is a flutamide liquid formulation commercially attractive?

It could support patients who cannot swallow capsules, but stability, taste, dose uniformity, preservative selection, and hepatic-risk communication would materially increase development complexity.

Does a new flutamide excipient combination create patent protection?

It can, if the combination is novel and produces non-obvious technical results. Routine substitution of lactose, starch, cellulose, or standard disintegrants is unlikely to provide strong protection by itself.

Can flutamide compete commercially with enzalutamide or darolutamide?

Only in price-sensitive or access-constrained markets. Flutamide is unlikely to compete directly on safety, dosing convenience, clinical positioning, or branded revenue potential.

References

1. U.S. Food and Drug Administration. (2023). Flutamide capsules prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. National Library of Medicine. (2024). Flutamide capsule: Drug label information. DailyMed.

4. National Library of Medicine. (2024). Flutamide tablet: Drug label information. DailyMed.

5. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.

6. U.S. Food and Drug Administration. (2001). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products. FDA.